Theriva Biologics Inc. (NYSE AMERICAN: TOVX) Stock Information | RedChip

Theriva Biologics Inc. (NYSE AMERICAN: TOVX) Listen to this Section


$0.20
+0.0041 ( +2.12% ) 133.4K

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Market Data


Insider Ownership Transactions

Total Amount Purchased: -1,030,000.00 | $ -203,116.00

Date Type Amount Purchased Purchaser
2023-12-15 Sale -110000.00 MONAHAN JOHN J
2023-12-15 Sale -110000.00 Kraws Jeffrey J
2023-12-15 Sale -110000.00 Wolf Jeffrey Alan
2023-12-15 Sale -700000.00 SHALLCROSS STEVEN A

SEC Fillings


Form Type Description Pages Date
8-k 8K-related 20 Aug 13, 2024
10-q Quarterly Reports 75 Aug 13, 2024
8-k 8K-related 15 Jul 31, 2024
8-k 8K-related 15 May 23, 2024
8-k 8K-related 13 May 16, 2024
8-k 8K-related 15 May 07, 2024
10-q Quarterly Reports 71 May 07, 2024
8-k 8K-related 14 May 02, 2024
8-k 8K-related 17 Apr 23, 2024
8-k 8K-related 17 Apr 22, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.